Skip to content
10-Q

Quarterly Report

Akoya Biosciences, Inc.

0001558370-24-015750

← back to feed
Filed
Nov 14, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 11, 2024 49.56M sh
Shares Diluted Q3 2024 · Sep 30, 2024 49.5M sh
Shares Diluted Q3 2024 · Sep 30, 2024 49.37M sh
Shares Diluted restated Q3 2024 · Sep 30, 2023 48.98M sh
Shares Diluted restated Q3 2024 · Sep 30, 2023 42.69M sh
Capex Q3 2024 · Sep 30, 2024 $1.41M
Capex Q3 2024 · Sep 30, 2023 $3.06M
Operating Cash Flow Q3 2024 · Sep 30, 2024 −$41.12M
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$45.32M
Long Term Debt Q3 2024 · Sep 30, 2024 $75.9M
Long Term Debt Q3 2024 · Dec 31, 2023 $75.25M
Cash And Equivalents Q3 2024 · Sep 30, 2024 $12.56M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $83.13M
Stockholders Equity Q3 2024 · Sep 30, 2024 $13.63M
Stockholders Equity Q3 2024 · Jun 30, 2024 $22.25M
Stockholders Equity Q3 2024 · Mar 31, 2024 $32.72M
Stockholders Equity Q3 2024 · Dec 31, 2023 $53.77M
Stockholders Equity Q3 2024 · Sep 30, 2023 $61.97M
Stockholders Equity Q3 2024 · Jun 30, 2023 $71.9M
Stockholders Equity Q3 2024 · Mar 31, 2023 $42.12M
Stockholders Equity Q3 2024 · Dec 31, 2022 $58.58M
Current Liabilities Q3 2024 · Sep 30, 2024 $27.99M
Current Liabilities Q3 2024 · Dec 31, 2023 $35.35M
Total Liabilities Q3 2024 · Sep 30, 2024 $116.34M
Total Liabilities Q3 2024 · Dec 31, 2023 $126.6M
Current Assets Q3 2024 · Sep 30, 2024 $76.86M
Current Assets Q3 2024 · Dec 31, 2023 $121.79M
Total Assets Q3 2024 · Sep 30, 2024 $129.97M
Total Assets Q3 2024 · Dec 31, 2023 $180.37M
Eps Diluted Q3 2024 · Sep 30, 2024 −$0.21
Eps Diluted Q3 2024 · Sep 30, 2024 −$0.96
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$0.26
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$1.23
Eps Basic Q3 2024 · Sep 30, 2024 −$0.21
Eps Basic Q3 2024 · Sep 30, 2024 −$0.96
Eps Basic Q3 2024 · Sep 30, 2023 −$0.26
Eps Basic Q3 2024 · Sep 30, 2023 −$1.23
Sga Expense Q3 2024 · Sep 30, 2024 $14.67M
Sga Expense Q3 2024 · Sep 30, 2024 $53.63M
Sga Expense restated Q3 2024 · Sep 30, 2023 $20.25M
Sga Expense restated Q3 2024 · Sep 30, 2023 $67.28M
Rd Expense Q3 2024 · Sep 30, 2024 $4.47M
Rd Expense Q3 2024 · Sep 30, 2024 $15.32M
Rd Expense restated Q3 2024 · Sep 30, 2023 $6.31M
Rd Expense restated Q3 2024 · Sep 30, 2023 $19.61M
Net Income Q3 2024 · Sep 30, 2024 −$10.53M
Net Income Q3 2024 · Sep 30, 2024 −$47.17M
Net Income Q3 2024 · Jun 30, 2024 −$13.15M
Net Income Q3 2024 · Mar 31, 2024 −$23.48M
Net Income Q3 2024 · Sep 30, 2023 −$12.92M
Net Income Q3 2024 · Sep 30, 2023 −$52.52M
Net Income Q3 2024 · Jun 30, 2023 −$20.8M
Net Income Q3 2024 · Mar 31, 2023 −$18.8M
Operating Income Q3 2024 · Sep 30, 2024 −$8.35M
Operating Income Q3 2024 · Sep 30, 2024 −$41.02M
Operating Income Q3 2024 · Sep 30, 2023 −$11.55M
Operating Income Q3 2024 · Sep 30, 2023 −$48.23M
Gross Profit Q3 2024 · Sep 30, 2024 $11.72M
Gross Profit Q3 2024 · Sep 30, 2024 $33.49M
Gross Profit Q3 2024 · Sep 30, 2023 $15.28M
Gross Profit Q3 2024 · Sep 30, 2023 $39.69M
Cost Of Revenue Q3 2024 · Sep 30, 2024 $7.09M
Cost Of Revenue Q3 2024 · Sep 30, 2024 $26.84M
Cost Of Revenue Q3 2024 · Sep 30, 2023 $9.94M
Cost Of Revenue Q3 2024 · Sep 30, 2023 $30.46M
Revenue Q3 2024 · Sep 30, 2024 $18.81M
Revenue Q3 2024 · Sep 30, 2024 $60.33M
Revenue Q3 2024 · Sep 30, 2023 $25.22M
Revenue Q3 2024 · Sep 30, 2023 $70.15M